Ligand Pharma (LGND) PT Raised to $332 at Stifel as Xoma Asset Acquisition Announced
Tweet Send to a Friend
Stifel analyst Annabel Samimy raised the price target on Ligand Pharma (NASDAQ: LGND) to $332.00 (from $255.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
